A 78-year-old male with persistent atrial fibrillation (CHA₂DS₂-VASc score of 4) is scheduled for a dual-chamber pacemaker implantation. He is currently on warfarin with a therapeutic INR. Based on the landmark BRUISE CONTROL trial, what is the most appropriate strategy for managing his anticoagulation around the time of surgery?
-
A
Stop warfarin 5 days prior, do not bridge with heparin, and resume warfarin after the procedure.
-
B
Stop warfarin 5 days prior and bridge with therapeutic low-molecular-weight heparin.
-
C
Continue uninterrupted warfarin, ensuring the INR is within the therapeutic range (2.0-3.0).
-
D
Switch to a direct oral anticoagulant (DOAC) two weeks before the procedure and hold it for 48 hours pre-procedure.